Key result
Procalcitonin is examined to determine whether it serves merely as a clinical biomarker or acts as an active mediator of disease.
Key points are not available for this paper at this time.
Should not yet alter procalcitonin use as biomarker; leaves open its potential role as active mediator.
Rush Medical College; Chicago, IL Address requests for reprints to: Susan S. Braithwaite, MD, Rush Medical College, 1653 W. Congress Parkway, Chicago, IL 60612.
No takes yet. Share an insight, caveat, or question.
Susan S. Braithwaite (1998) studied this question. Procalcitonin is examined to determine whether it serves merely as a clinical biomarker or acts as an active mediator of disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: